Using peripheral nerve stimulation to treat pain from chemotherapy-induced nerve damage
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
NA · M.D. Anderson Cancer Center · NCT06162403
This study is testing if a treatment called peripheral nerve stimulation can help reduce pain for people suffering from nerve damage caused by chemotherapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06162403 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of peripheral nerve stimulation (PNS) in alleviating pain associated with chemotherapy-induced peripheral neuropathy (CIPN). Participants will undergo assessments of pain intensity and various sensory and functional tests before and after receiving PNS treatment. The study will focus on measuring changes in pain levels, sensory function, and overall disability related to pain. It is conducted at the MD Anderson Cancer Center, a leading institution in cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-85 with chronic CIPN lasting at least 90 days and a baseline pain score of 4 or higher.
Not a fit: Patients with cognitive dysfunction, recent substance abuse, or certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce pain and improve quality of life for patients suffering from CIPN.
How similar studies have performed: While the use of peripheral nerve stimulation is a promising approach, its specific application for CIPN is still being explored and has not been widely tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center * Participants reports baseline pain ≥ 4 (0-10 scale, NRS) * Participants between ages 18-85 years old * Participants who have completed chemotherapy within the previous year at the time of enrollment Exclusion Criteria: * Participants with cognitive dysfunction * Participants with recent history (\<6 months) of drug or alcohol abuse * Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Participants with allergies to local anesthesia, steroids, or adhesives * Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Saba Javed, MD — M.D. Anderson Cancer Center
- Study coordinator: Saba Javed, MD
- Email: sjaved@mdanderson.org
- Phone: (713) 792-9530
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Peripheral Nerve Stimulation, Chemotherapy-induced Peripheral Neuropathy